Synovium News and Research

RSS

Too much tea raises the risk of rheumatoid arthritis: Study

Rheumatoid arthritis (RA) a severely debilitating inflammatory disease of the joints is on the rise worldwide. It leads to severe pain, stiffness, swelling and loss of movement of joints like knees, wrist and even fingers. RA affects women more than men. RA occurs in people who develop a rogue immune system that attacks the tissue that lines the joint cavities called the synovium leading to degeneration of the joints and the symptoms of the disease. In 1995 36.4 per 100,000 women were diagnosed with RA whereas in 2005 the number rose to 54 per 100,000 women.

20 Jun 2010

Expression of BCRP in RA patients may indicate higher disease activity, predict resistance to DMARDs

The expression of a transporter protein called the Breast Cancer Resistance Protein in rheumatoid arthritis patients may indicate higher disease activity and could be a barrier to the effectiveness of disease-modifying antirheumatic drugs, according to the results of a study presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy.

18 Jun 2010

VBL presents positive preclinical data on VB-201 for rheumatoid arthritis at EULAR

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating that VB-201 possesses anti-inflammatory properties and effectively reduced the symptoms of arthritis in experimental models.

17 Jun 2010

MorphoSys granted U.S. patent on antibodies against GM-CSF to treat inflammatory disorders

MorphoSys AG and the University of Melbourne announced today that the U.S. Patent & Trademark Office (USPTO) has confirmed that it will issue U.S. Patent No. 7,455,836, covering key uses of antibodies against GM-CSF.

25 Nov 2008

MorphoSys announces publication of first MOR103 data

MorphoSys AG announced today the publication of a first data package for its most advanced proprietary drug development program MOR103, a fully human HuCAL antibody directed against GM-CSF, in the journal "Molecular Immunology".

2 Sep 2008

Research finds novel mechanism for synovial inflammation in degenerative arthritis

The most common degenerative joint disease, osteoarthritis (OA) is marked by the breakdown of articular cartilage, which is the type of cartilage that lines the ends of most limb bones.

29 Oct 2007

Decoy receptor 3 expressed in rheumatic synovial fibroblasts protects the cells against Fas-induced apoptosis

A complex autoimmune disease, rheumatoid arthritis (RA) is characterized by chronic inflammation and progressive joint damage. This process begins with hyperplasia, or excessive increase in size and thickness, of synovial tissue. Along with provoking cartilage and bone destruction, this abnormal tissue growth is resistant to apoptosis, the natural cell death vital to the generation of healthy new cells.

30 Mar 2007

Targeting the inflamed synovium: The quest for specificity

In the April 2006 issue of Arthritis & Rheumatism, noted rheumatology specialists with Kings College London, Dr. Toby Garrood and Dr. Costantino Pitzalis offer an overview of recent breakthroughs and a preview of future directions in this critical quest for specificity.

4 Apr 2006

Unexpected rheumatoid arthritis discovery

What makes joints in people with rheumatoid arthritis, and related conditions like Lyme disease or lupus, so susceptible to attack by the body's immune system, leading to painful flare-ups and deterioration? The answer may surprise you.

17 Feb 2006

Adalimumab and methotrexate is about five times more effective than methotrexate alone for rheumatoid arthritis

For people with long-standing rheumatoid arthritis, combined treatment with the new "biologic" drug adalimumab and methotrexate is about five times more effective than methotrexate alone, according to a new systematic review of studies.

15 Aug 2005

Expression profiles and functional analyses of Wnt-related genes in human joint disorders

The cellular signaling protein Wnt, which is involved in embryonic development and cancer, contributes to disease progression of both rheumatoid arthritis and osteoarthritis.

26 Jun 2005

Study to determine how people with rheumatoid arthritis evaluate improvements in disease symptoms

The study will examine how much of an improvement in pain, stiffness, function and other symptoms is needed before patients consider the change important.

7 Aug 2004

New clinical study to determine how people with rheumatoid arthritis evaluate improvements in disease symptoms

A new clinical study to determine how people with rheumatoid arthritis (RA) evaluate improvements in disease symptoms will be carried out by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the Department of Health and Human Services' National Institutes of Health.

5 Aug 2004